^

Health And Family

Vaccines prevent severe COVID-19, even from Delta — study

Agence France-Presse
Vaccines prevent severe COVID-19, even from Delta â study
Members of the public speak with health workers as they receive a dose of Covid-19 vaccine at a temporary vaccination centre set up in the cafe "Le Diplomate" in the Fives district of Lille, northern France, on September 18, 2021, during the Covid-19 pandemic. Fabienne Plouvier, owner of the cafe, explains that the idea of set up a temporary vaccination centre in her establishment had come to her by dint of listening to all the customers who were afraid of being vaccinated. To reassure them, Plouvier, had the vaccine come to them, rather than sending them to be vaccinated: "Bringing the vaccines to my establishment, it allows them to feel reassured, and my presence helps them a lot."
AFP/DENIS CHARLET

PARIS, France — Vaccination is highly effective at preventing severe cases of Covid-19, even against the Delta variant, a vast study in France has shown.

The research published Monday — focusing on prevention of severe Covid and death, not infection — looked at 22 million people over 50 and found those who had received jabs were 90 percent less likely to be hospitalised or die.

The results confirm observations from the US, the UK and Israel, but researchers say it is the largest study of its kind so far.

Looking at data collected starting in December 2020, when France launched its jab campaign, the researchers compared the outcomes of 11 million vaccinated people with 11 million unvaccinated subjects.

They formed pairs matching an unvaccinated individual with a vaccinated counterpart from the same region and of the same age and sex, tracking them from the date of the vaccinated person's second jab to July 20.

Starting 14 days after a second dose, a vaccinated subjects' risk of severe Covid was reduced by 90 percent, according to the research conducted by Epi-Phare, an independent medicines safety research group that works closes with the French government.

Vaccination appears to be nearly as effective against for the Delta variant, with 84 percent protection for people 75 and older and 92 percent for people 50-75.

That estimate, however, is only based on a month of data, since the variant became dominant in France only in June.

"The study should be followed up to include results from August and September," epidemiologist Mahmoud Zureik, the head of Epi-Phare, told AFP.

The study covers vaccination with the Pfizer/BioNtech, Moderna and AstraZeneca jabs, but not Jannsen which was authorised much later and is far less widely used in France.

The results also suggest that over the period of study — up to five months — vaccination protection against severe Covid did not diminish.

COVID-19 VACCINES
As It Happens
LATEST UPDATE: October 15, 2021 - 2:45pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

October 15, 2021 - 2:45pm

An expert committee recommends a booster dose of Moderna's anti-Covid vaccine in the United States for certain at-risk groups, a month after making a similar decision for the Pfizer shot.

The opinion submitted by the advisory committee of the Food and Drug Administration -- composed of researchers, epidemiologists and infectious disease experts -- is not binding, but it is rare for the FDA not to follow it. 

After a day of debate, the experts decided to authorize a booster dose of Moderna for three categories of people: the over-65s, people aged between 18 and 64 who are at a higher risk of developing a severe version of the coronavirus, and those whose work may involve frequent exposure to the virus. — AFP

October 13, 2021 - 6:55am

G20 trade ministers on Tuesday promise to work towards a fair distribution of Covid-19 vaccines by lifting export restrictions and making the trade system more transparent.

Their final statement, adopted after a meeting in Sorrento, southern Italy, was a sign of the return of multilateralism, says Italian Foreign Minister Luigi Di Maio.

"We have to ensure that there is greater circulation of vaccines and that there are production factories in the developing countries," French trade minister Franck Riester says. — AFP

October 2, 2021 - 10:22am

COVID vaccinations will be compulsory for all students in California, the state's governor announced Friday — a first in the United States, where vaccine hesitancy has slowed efforts to end the pandemic.

The plan will be phased in as Food and Drug Administration regulators grant full approval for use in younger age groups.

California "will require our kids to get the Covid-19 vaccine to come to school," said Governor Gavin Newsom.

"Our schools already require vaccines for measles, mumps and more. Why? Because vaccines work. This is about keeping our kids safe and healthy."

The Pfizer-BioNTech vaccine has been granted full FDA approval for those age 16 and up. — AFP

September 28, 2021 - 3:45pm

France's pharmaceutical giant Sanofi, which has lagged rivals in producing new generation Covid-19 vaccines, said Tuesday it had decided to halt development of an mRNA candidate and focus on another vaccine against coronavirus.

Despite positive results at phase one and two trials, the candidate will not go to the third and final phase, Sanofi said, as they believed it would arrive too late to market with 12 billion anti-Covid doses already due to be produced by the end of the year.

Results from phase three trials of the other vaccine, developed with Britain's GlaxoSmithKline are expected before the end of 2021. — AFP

September 24, 2021 - 2:16pm

A committee of US health experts declines to approve Pfizer booster shots for individuals at high risk of COVID-19 exposure due to their jobs, despite authorization from a different agency just the night before. 

The decision has contributed to growing confusion about the campaign for booster doses in the United States, which the administration of President Joe Biden announced in mid-August but has since lost momentum. 

The Centers for Disease Control and Prevention (CDC) committee voted Thursday to recommend a third dose of Pfizer's vaccine for people over age 65 and for those with underlying conditions who are at risk of developing a severe case of COVID-19. — AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with